A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.
Name: Tazemetostat
There is one SNP
JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---